Triplet Therapy May Be on the Horizon for BRAF-Mutant Melanoma

Silas Inman @silasinman
Published: Wednesday, Feb 21, 2018
Antoni Ribas, MD, PhD

Antoni Ribas, MD, PhD
The past decade of drug discovery has brought a dramatic expansion in the number of new therapies to treat patients with advanced or metastatic melanoma in 2 modalities: checkpoint blockade immunotherapies and molecularly targeted drugs. In both areas, these therapeutic categories have grown from single-agent regimens into combination strategies.


Figure. Merging Strategies in Melanoma Therapy1

The triplet strategies combine a monoclonal antibody targeting either PD-1 or PD-L1 with drugs that inhibit BRAF and MEK kinases, which are key components of the protein signaling pathway within the melanoma cell.


Table. Selected Melanoma Trials Exploring 3-Drug Combinations

“Three phase I trials attest to the overall safety of combined full-dose therapy with a BRAF and a MEK inhibitor with anti–PD-1/PD-L1 and provide early encouraging evidence of combined efficacy,” Ribas said. “There are toxicities, but they are usually responsive to stopping the targeted therapies for a little bit of time and then restarting.”
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication